Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma

Blood

Volumn 89, Issue 8, 1997, Pages 2994-2998

  Wooldridge, James E ^a   Ballas, Zuhair ^a   Krieg, Arthur M ^a   Weiner, George J ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; INTERLEUKIN 2; MONOCLONAL ANTIBODY; OLIGODEOXYNUCLEOTIDE;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

EID: 0030900680     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.8.2994     Document Type: Article

References (20)

1. Messina JP, Gilkeson GS, Pisetsky DS: Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 147:1759, 1991
2. Klinman DM, Yi A-K, Beaucage SL, Conover J, Krieg AM: CpG motifs expressed by bacterial DNA rapidly induce lymphocytes to secrete IL-6, IL-12, and IFN-γ. Proc Natl Acad Sci USA 93:2879, 1996
3. Krieg AM, Yi A-K, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546, 1995
4. Ballas ZK, Rasmussen WL, Krieg AM: Induction of natural killer activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157:1840, 1996
5. Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T, Tokunaga T: DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol 36:983, 1992
6. Yamamoto S, Kuramoto E, Shimada S, Tokunaga T: In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG. Jpn J Cancer Res 79:866, 1988
7. Stacey KJ, Sweet MJ, Hume DA: Macrophages ingest and are activated by bacterial DNA. J Immunol 157:2116, 1996
8. Shimada S, Yano O, Tokunaga T: In vivo augmentation of natural killer cell activity with a deoxyribonucleic acid fraction of BCG. Jpn J Cancer Res 77:808, 1986
9. Cowdery JS, Chace JH, Yi A-K, Krieg AM: Bacterial DNA induces NK cells to produce interferon gamma in vivo and increases the toxicity of lipopolysaccharide. J Immunol 156:4570, 1996
10. Yi A-K, Klinman DM, Martin TL, Matson S, Krieg AM: Rapid immune activation by CpG motifs in bacterial DNA. J Immunol 157:5394, 1996
11. Berinstein N, Levy R: Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2. J Immunol 139:971, 1987
12. Maloney DG, Kaminski MS, Burowski D, Haimovich J, Levy R: Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: Characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 4:191, 1986
13. Starnes CO, Carroll WL, Campbell MJ, Houston LL, Apell G, Levy R: Heterogeneity of a murine B cell lymphoma. Isolation and characterization of idiotypic variants. J Immunol 141:333, 1988
14. Weiner GJ, Kaminski MS: Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma. J Immunol 142:343, 1989
15. Weiner GJ, Kaminski MS: Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma. J Immunol 144:2436, 1990
16. Cox DR: Regression models and life-tables (with discussion). J R Stat Soc Series B 34:187, 1972
17. Kaminski MS, Kitamura K, Maloney DG, Campbell MJ, Levy R: Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J Immunol 136:1123, 1986
18. Coley WB: The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases. Am J Med Sci 105:487, 1893
19. Coley WB: Treatment of inoperable malignant tumors with the toxins of Erysipelas and the Bacillus prodigiosus. Am J Med Sci 108:183, 1894
20. Wiemann B, Starnes CO: Coley's toxins, tumor necrosis factor and cancer research: A historical perspective. Pharmacol Ther 64:529, 1994